IRBM unleashes its passion for science on the global drug discovery market
A conversation with Matteo Liguori, Managing Director of IRBM
IRBM publishes in Nature Scientific Reports on the Janus effect of glucocorticoids on the differentiation of muscle fibro/adipogenic progenitors
Fibro-adipogenic progenitors (FAPs) are known to cause muscle impairment in non-physiological settings, such as aging and myopathies, by promoting fibrosis and fat infiltration. IRBM and their collaborators at the University of Rome Tor Vergata, screened a library of 1,120 FDA/EMEA…
IRBM shares their experience on developing and maintaining business continuity plans during the COVID19 outbreak
As the world is coming to terms with the terrific speed of the COVID19 pandemic and how it can dramatically change people, societies and even nations; our hearts go out to the many people who have been affected by this…
IRBM comparte su experiencia en el desarrollo y mantenimiento de planes de continuidad para las empresas durante el brote de COVID19
En este momento en el que el mundo se enfrenta a la tremendamente rápida difusión de la pandemia de Covid-19 y a los drasticos cambios en las personas, las sociedades e incluso las naciones, nuestros corazones están con la gran…
IRBM partage son expérience dans l’élaboration et le maintien de plans de continuité des activités pendant l’épidémie de COVID19
Le monde entier est confronté à la propagation très rapide du Covid 19 et personne ne sait comment le monde évoluera suite à cette crise. Toutes nos pensées vont vers ceux déjà atteints par ce virus sans précédent et nous…
IRBM condivide la propria esperienza nello sviluppo e nel mantenimento dei piani di continuità aziendale durante l’epidemia di COVID19
Mentre il mondo si ritrova a fare i conti con la terribile diffusione della pandemia del Covid19 e come questa possa modificare drasticamente le abitudini delle persone, delle società e persino delle nazioni, il nostro pensiero è rivolto a tutti…
The Covid-19 vaccine race (The Sunday Telegraph)
IRBM’s ADVENT GMP facility was recently mentioned in a Sunday Telegraph article covering the race to find a vaccine for COVID 19. The article talks about our collaboration with the Jenner Institute, Oxford University, who will produce the adenovirus-based vaccine…
Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors
Stopping the night time kissing bug: IRBM’s scientists recently published a Bioorganic & medicinal chemistry paper on a novel class of inhibitors for Chagas Disease, an infectious disease caused by the parasite Trypanosoma cruzi, spread by an insect commonly referred…
Biomarkers Series UK
Manuel Daldin, Scientist - High Throughput Biology and Screening and Heidi Kingdon Jones, Global VP Business Development are attending the Biomarker conference in Manchester. Manuel will be presenting on the “development and validation of an assay to detect mutant huntingtin…
The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
The Jenner Institute, Oxford University, UK and Advent Srl – an IRBM company, Pomezia,Italy - are continuing their long-standing history of collaboration, by announcing today a new agreement to develop a novel vaccine for coronavirus. The Jenner Institute at the…